Evidence map›Paper›PMID 38275541›Full record

ArticleHealthcare (Basel, Switzerland)2024

Aligning Cancer Research Priorities in Europe with Recommendations for Conquering Cancer: A Comprehensive Analysis.

Denis Horgan, Marc Van den Bulcke, Umberto Malapelle, Nicola Normanno, Ettore D Capoluongo, Arsela Prelaj, Carmelo Rizzari, Aliki Stathopoulou, Jaya Singh, Marta Kozaric and 15 more

Open access · goldAbstract read
In one paragraph

Article in Healthcare (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Bridging the Gap: Scenario Planning for Science and Technology in Breast Cancer.Medical journal of the Islamic Republic of Iran · 2025
    Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 18 institutions in 7 countries.

Denis HorganEuropean Alliance for Personalised Medicine, 1040 Brussels, Belgium.
Marc Van den BulckeBelgian Cancer Centre, Sciensano, 1050 Brussels, Belgium.
Umberto MalapelleDepartment of Public Health, University Federico II of Naples, 80138 Naples, Italy.ORCID 0000-0003-3211-9957
Nicola NormannoIstituto Nazionale Tumori "Fondazione G. Pascale"-IRCCS, 80131 Naples, Italy.ORCID 0000-0002-7158-2605
Ettore D CapoluongoDipartimento di Eccellenza in Medicina Molecolare e Biotecnologie Mediche, Università Federico II, 80138 Naples, Italy.
Arsela PrelajDepartment of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, 20133 Milan, Italy.ORCID 0000-0002-3863-088X
Carmelo RizzariUnità di Ematologia Pediatrica, Fondazione MBBM, Università di Milano-Bicocca, 20126 Monza, Italy.ORCID 0000-0002-4828-3893
Aliki StathopoulouEuropean Cancer Patient Coalition, 1000 Brussels, Belgium.
Jaya SinghEuropean Alliance for Personalised Medicine, 1040 Brussels, Belgium.
Marta KozaricEuropean Alliance for Personalised Medicine, 1040 Brussels, Belgium.
France DubeAstra Zeneca, Concord Pike, Wilmington, DE 19803, USA.
Manuel OttavianoDepartamento de Tecnología Fotónica y Bioingeniería, Universidad Politècnica de Madrid, 28040 Madrid, Spain.
Stefania BocciaSection of Hygiene, Department of Life Sciences and Public Health, Università Cattolica del Sacro Cuore, 20123 Rome, Italy.ORCID 0000-0002-1864-749X
Gabriella PravettoniDepartment of Oncology and Hemato-Oncology, University of Milan, 20122 Milan, Italy.
Ivana CattaneoNovartis Farma SpA, 20154 Milano, Italy.
Núria MalatsGenetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain.ORCID 0000-0003-2538-3784
Reinhard BuettnerLung Cancer Group Cologne, Institute of Pathology and Medical Faculty, Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, 50937 Cologne, Germany.ORCID 0000-0001-8806-4786
Karim LekadirArtificial Intelligence in Medicine Lab (BCN-AIM), Universitat de Barcelona, 08007 Barcelona, Spain.
Francesco de LorenzoEuropean Cancer Patient Coalition, 1000 Brussels, Belgium.
Patricia BlancImagine for Margo, 78100 Saint-Germain-en-Laye, France.
Catherine Alix-PanabieresLaboratory of Rare Human Circulating Cells, University Medical Center of Montpellier, 34093 Montpellier, France.ORCID 0000-0002-6401-2903
Sara BadrehCancer Childhood International, 1200 Vienna, Austria.
Paul HofmanLaboratory of Clinical and Experimental Pathology, Pasteur Hospital, Université Côte d'Azur, 06000 Nice, France.ORCID 0000-0003-0431-9353
Eric SolaryINSERM U1287, Gustave Roussy Cancer Campus, 94805 Villejuif, France.ORCID 0000-0002-8629-1341
Ruggero De MariaInstitute of General Pathology, Catholic University of the Sacred Heart, 20123 Rome, Italy.
European CanCer Organisation · BEUniversità Cattolica del Sacro Cuore · ITFondazione IRCCS Istituto Nazionale dei Tumori · ITIstituto Nazionale Tumori IRCCS "Fondazione G. Pascale" · ITNovartis (Italy) · ITOspedale Cannizzaro · ITSam Higginbottom Institute of Agriculture · INSciensano (Belgium) · BESpanish National Cancer Research Centre · ESUniversidad Politécnica de Madrid · ESUniversitat de Barcelona · ESUniversité Côte d'Azur · FRUniversité de Montpellier · FRUniversité Paris-Sud · FRUniversity Hospital Cologne · DEUniversity of Milan · ITUniversity of Milano-Bicocca · ITWilmington University · US

Funding

European Union 101080005European Union 101080009
6 · The paper itself

Abstract

Improvements in cancer care require a new degree of collaboration beyond the purely medical sphere, extending deeply into the world of other stakeholders-preeminently patients but also the other stakeholders in the hardware and software of care. Cancer remains a global health challenge, necessitating collaborative efforts to understand, prevent, and treat this complex disease. To achieve this goal, a comprehensive analysis was conducted, aligning the prioritization of cancer research measures in 13 European countries with 13 key recommendations for conquering cancer in the region. The study utilized a survey involving both patients and citizens, alongside data from IQVIA, a global healthcare data provider, to assess the availability and access to single-biomarker tests in multiple European countries. The results revealed a focused approach toward understanding, preventing, and treating cancer, with each country emphasizing specific research measures tailored to its strengths and healthcare objectives. This analysis highlights the intricate relationship between research priorities, access to biomarker tests, and financial support. Timely access to tests and increased availability positively influence research areas such as cancer prevention, early detection, ageing, and data utilization. The alignment of these country-specific measures with 13 recommendations for conquering cancer in Europe underscores the importance of tailored strategies for understanding, preventing, and treating cancer.

Indexed as

cancerpatientspersonalized medicinepolicymakersprioritiesrecommendationsreimbursementresearchsurvey

Identifiers

PMID38275541
PMCPMC10815829
OpenAlexW4391024815

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.